To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

1. 01

   How would reversing pharmacy access to mifepristone affect patients in rural areas or regions with limited abortion clinics?

2. 02

   What evidence supports or challenges the FDA's January 2023 decision that retail pharmacies could safely dispense mifepristone?

3. 03

   If this bill passes, what authority would remain for the FDA to adjust drug safety rules based on new medical evidence?

Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.